mcp 1  (R&D Systems)

Journal: Frontiers in Immunology

Article Title: Dysregulated hyaluronan metabolism drives inflammation and angiogenesis in proliferative diabetic retinopathy

doi: 10.3389/fimmu.2026.1724199

Figure Lengend Snippet: Human retinal Müller glial cells were left untreated or treated with ultra-low molecular weight hyaluronan (ULMW-HA) (50 µg/mL) for 24 (h) (A) Protein expression of phospho-ERK1/2 and phospho-NFκB in cell lysates was determined by Western blot analysis. Levels of high mobility group box-1 (HMGB1) were quantified in the culture media by ELISA. Results are expressed as mean ± standard deviation from three different experiments each performed in triplicate (*p < 0.05; independent t-test). (B) Human retinal Müller glial cells were left untreated or treated with ULMW-HA, ULMW-HA plus BAY11-7085 (5 µM) or (C) ULMW-HA plus U-0126 (5 µM). Levels of vascular endothelial growth factor (VEGF), angiopoietin and monocyte chemotactic protein-1 (MCP-1/CCL2) were quantified in the culture media by ELISA. Results are expressed as mean ± standard deviation or standard error of mean from three different experiments each performed in triplicate. One-way ANOVA and independent t-test were used for comparisons between three groups and two groups, respectively. *p < 0.05 compared with values obtained from untreated cells; #p < 0.05 compared with ULMW-HA plus BAY11–7085 or U-0126 treated cells. (D, E) Human retinal Müller glial cells were left untreated or treated with high glucose (HG) (25 mM), cobalt chloride (CoCl 2 ) (300 µM) or tumor necrosis factor-α (TNF-α) (5 ng/mL) with or without apigenin (10 µg/mL) for 24 (h) For HG treatment, cultures containing 25 mM mannitol were used as a control. Levels of monocyte chemotactic protein-1 (MCP-1/CCL2) (D) and vascular endothelial growth factor (VEGF) (E) were quantified in the culture media by ELISA. The results are expressed as mean ± standard deviation from three different experiments each performed in triplicate. One-way ANOVA and independent t-test were used for comparisons between three and two groups, respectively. *p < 0.05 compared with values obtained from control cells. #p < 0.05 compared with values obtained from stimulated cells.

Article Snippet: Enzyme-linked immunosorbent assay (ELISA) kits for human Hyal-1 (Cat No DY7358), human Hyaluronan (Cat No DY3614-05), and human syndecan-1 (Cat No DY2780), human vascular endothelial growth factor (VEGF) (Cat No DY293B), human monocyte chemoattractant protein-1 (MCP-1/CCL2) (Cat No DY279), human matrix metalloproteinase-9 (MMP-9) (Cat No DY911) and human angiopoietin-2 (Cat No DY623) were purchased from R&D Systems.

Techniques: Molecular Weight, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Standard Deviation, Control

Journal: Brazilian Dental Journal

Article Title: Chemoattractive potential of stem cells from apical papilla in peripheral blood monocytes: an in vitro study

doi: 10.1590/0103-644020256694

Figure Lengend Snippet: Production of CCL2 quantified by ELISA assay in SCAP conditioned medium (CM-SCAP). Bars show the mean and standard deviation of the experiment (N=3) (A). Viability of monocytes stimulated with decreasing dilutions of SCAP supernatant (CM) compared with control (proliferation medium alone). Absorbance (570nm) data obtained from the MTT assay after 24 h of stimulus exposure (B). Fluorescence data obtained by Alamar Blue assay at experimental time of 24 h. Conditioned medium by SCAP (CM-SCAP) diluted ½ in the presence or not of a CCL2 neutralizer (CM-SCAP + α-CCL2) compared to control (proliferation medium alone) and Recombinant Human CCL2 (CCL2 rH) (C). The result showed the mean and standard deviation of the experiments performed in triplicate. Different letters represent statistical differences between groups. (One-Way ANOVA with Tukey's test, p<0.05) (B and C).

Article Snippet: 300 ng/ml of Recombinant Human CCL2 (279-MC-010 R&D Systems) was used for positive control, while α-MEM 10% was the negative control.

Techniques: Enzyme-linked Immunosorbent Assay, Standard Deviation, Control, MTT Assay, Fluorescence, Alamar Blue Assay, Recombinant

Journal: PLOS One

Article Title: Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent

doi: 10.1371/journal.pone.0338780

Figure Lengend Snippet: a. 125 I-CCL2 Pe in the presence of 10 µg/mL CCL2 compared to PBS vehicle. b. 131 I-Alb Pe in the presence of 10 µg/mL CCL2 compared to PBS vehicle. c. 125 I-CCL2 Pe corrected for non-specific leakage as quantified by 131 I-Alb Pe in the presence 10 µg/mL CCL2 compared to PBS vehicle. a-c. One differentiation was performed with n = 7-8 transwells per group. **p < 0.01, ***p < 0.001 (Unpaired two-tailed t-test). Means are displayed with their SD.

Article Snippet: The chloramine-T method was used to radioactively label recombinant carrier-free human CCL2 (R & D Systems, 279-MC-050/CF) with 125 I and bovine serum albumin (BSA, Sigma cat no. 17030-100G) with 131 I, as described previously [ ].

Techniques: Two Tailed Test

Journal: PLOS One

Article Title: Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent

doi: 10.1371/journal.pone.0338780

Figure Lengend Snippet: a. 125 I-CCL2 Pe in the presence of 20 U/mL heparin or 10 µM RS504393 (CCR2 antagonist) compared to control (“Ctrl”). b. 131 I-Alb Pe in the presence of 20 U/mL heparin or 10 µM RS504393 compared to an untreated control group. c. 125 I-CCL2 Pe corrected for non-specific leakage as quantified by 131 I-Alb Pe in the presence of 20 U/mL heparin or 10 µM RS504393 compared to an untreated control group. a-c. ***p < 0.001, ****p < 0.0001 (One-way ANOVA with Tukey’s multiple comparisons test). d. Comparison of 125 I-CCL2 and 131 I-Alb Pe in the untreated control group. ****p < 0.0001 (Unpaired two-tailed t-test). a-d. One differentiation was performed with n = 5-6 transwells per group. Means are displayed with their SD.

Article Snippet: The chloramine-T method was used to radioactively label recombinant carrier-free human CCL2 (R & D Systems, 279-MC-050/CF) with 125 I and bovine serum albumin (BSA, Sigma cat no. 17030-100G) with 131 I, as described previously [ ].

Techniques: Control, Comparison, Two Tailed Test

Journal: PLOS One

Article Title: Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent

doi: 10.1371/journal.pone.0338780

Figure Lengend Snippet: a. Representative immunocytochemistry of Heparan Sulfate clone F58-10E4 (HS(10E4)) (red) and DAPI (blue) in vehicle or HSase I, II, and III-treated iBECs. b-c. Immunofluorescence analysis of HS(10E4) mean fluorescence intensities (MFI) relative to DAPI area (b) or total HS(10E4) area relative to DAPI area (c). d-e. 125 I-CCL2 (d) or 131 I-Alb in the presence of 0.25 U/ml HSase I, II, and III compared to vehicle. f. 125 I-CCL2 Pe corrected for non-specific leakage as quantified by 131 I-Alb Pe in the presence of 0.25 U/ml HSase I, II, and III compared to vehicle. One differentiation was performed with n = 7-8 transwells per group. *p < 0.05, ***p < 0.001 (Unpaired two-tailed t-test). Means are displayed with their SD. Figure created with BioRender.

Article Snippet: The chloramine-T method was used to radioactively label recombinant carrier-free human CCL2 (R & D Systems, 279-MC-050/CF) with 125 I and bovine serum albumin (BSA, Sigma cat no. 17030-100G) with 131 I, as described previously [ ].

Techniques: Immunocytochemistry, Immunofluorescence, Fluorescence, Two Tailed Test

Journal: PLOS One

Article Title: Transport of CCL2 across an induced pluripotent stem cell-derived in vitro model of the human blood-brain barrier is heparan sulfate-dependent

doi: 10.1371/journal.pone.0338780

Figure Lengend Snippet: a. Molecular structure of GalNAz. b. On day 3 post-subculture, transwells were organized into treatment groups such that TEER means were approximately equal and treated with GalNAz or DMSO (vehicle control).Transwells were re-treated on day 6 post-subculture, and the effects on TEER (c), 125 I-CCL2 Pe (d) and 131 I-Alb Pe (e) were measured on day 9 post-subculture. f. For each transwell, 125 I-CCL2 Pe was corrected for non-specific leakage as quantified by 131 I-Alb Pe. b-f. **p < 0.01, ***p < 0.001 (Unpaired two-tailed t-test). One differentiation was performed with n = 9 transwells treated per group. Means are displayed with their SD. Figure created with BioRender.

Article Snippet: The chloramine-T method was used to radioactively label recombinant carrier-free human CCL2 (R & D Systems, 279-MC-050/CF) with 125 I and bovine serum albumin (BSA, Sigma cat no. 17030-100G) with 131 I, as described previously [ ].

Techniques: Control, Two Tailed Test